The sales of cancer drugs and related services by entities (organizations, sole traders, and partnerships) that create oncology drugs to diagnose and treat all forms of malignancies constituting the oncology drugs market. This industry comprises manufactures of medications for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain cancer, and other cancers with chemotherapy, surgery, and radiotherapy. Drugs are developed by the pharmaceutical industry to diagnose, cure, or prevent diseases. Since 2015, the worldwide oncology drugs market has grown at a compound annual growth rate (CAGR) of 9.8%, reaching over $167.9 billion in 2019. At a CAGR of 9.7%, the market is predicted to rise modestly from $201.1 billion in 2021 to $284.5 billion in 2023. The market is predicted to level out in 2025, reaching $284.5 billion and $412.9 billion by 2030.
Important Alert:
X
Title : Deubiquitylase USP31 induces autophagy and promotes the progression in lung squamous cell carcinoma cells by stabilizing E2F1 expression
Qian Zhang, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, China
Title :
Luca Roncati, University of Modena and Reggio Emilia, Italy
Title :
Bene Ekine-Afolabi, ZEAB Therapeutic Ltd, United Kingdom
Title :
K.P.Mishra, Asian Association for Radiation Research, India